Nathan L. Mata
looking late-stage we're is you're of looking to right? about of which efficacy inhibitors, which inflammatory an a of asking treatment X talking happy because are based the fact disease, very is you're the response, inflammatory belling a an Thank it complement the Yes, you at same Bruce. is when So essentially in phenomenon disease, address this relevant spectrums question. different at it, The for that I'm GA.
early inflammation lesions, target these very these lesions, to And that geographic patient the we're nascent is aiming or on. inflammation. there that's So prior when going the on little population to patients early developed atrophy
trying get And So put this inflammatory retina these is by the inhibitors disease, just you're with your to time inflammatory the and complement to response. basically the you fire on out fire. well
underlying is, have have it's you it we underlying But stress, still whatever still fact, mitochondrial like you whether in pathology, this or oxidation this believe pathology. it's bisretinoids or
so all it's up really is border, And but you're raging doing fire the putting at within. still the
What we're which that is certainly, toxic molecules, the these have [indiscernible] earliest early-stage on doing of early go pharmacotherapy with implicated addresses in these Stargardt's. been byproducts, in in And incipient all disease disease in GA.
to who actually believe the we were again, the greatest of patients level smaller and than speaks protein -- because because achieved just [indiscernible] effect treatment retinal data a lesions that So mean. also study for but reduction, certain of because their the sort was of binding that our in not
lesions XX at than So or when look XX X where at lesions much even those by to And X-millimeter size. characterized inflammation. are we're larger, were millimeters complement in lesions talking those effective, the less about larger baseline. you And are is inhibitors study again,
very So this and difference disease, addressing is addressing complement our very that is between the pharmacotherapy they're early-stage we're disease. the and inhibitors late-stage biggest
regard terrible for With phenomenon these a the vasculitis, certainly it's [indiscernible] is patients. and blinding to which
the some exactly it both appellate they was still there's it's needle, first that patients compound, gauge unknown both of molecules, I thought rare, very compound the then response pegylation it, certain what's have maybe causing was and the thought pegylation. and Ivera ] think because to the could only of isolated be these get [ They it that. fact it's the it and immune due and
effects see So in the for even very it, should only very is Ivera patients the though the pegylation patients, seen these should -- likely drug. appellate in it then reason the be if, we side we've in with also treated fact, treated as
patients. that's it a meaningful will a those So inhibitors is in for about risk, to really years. can mean with We all meaningful again, significant very jury it the a complement a have still after not important is that we this And out. a the treatment these clinically fact, getting know that that, point patients I safety X effect until patient intravitreal safety know is say because treated clinically that risk
burden benefit ours, said endure So be for but much actually a there's patients like there those tremendous to function. visual the they fact a in for same a could injections treatment before X years, perhaps X over The is an visual a period oral burden. will be treatment acuity lower to and getting of therapy these
lot believe between So complement early, both safety because to what like an years. the as well differentiation with getting it's case for of cancer we anything with that retinal disease, there's there's inhibitors a anything early just the from respiratory and a perspective we're as in perspective that is goes by doing a like intervention degeneration curative on key long-term and in where disease years efficacy
stage. So if can you get late vision in the early you prevent the of loss
this important. make that it but just very differentiation to because I Bruce, want is hope was I enough, So clear
